STOCK TITAN

DermTech, Inc. - DMTK STOCK NEWS

Welcome to our dedicated page for DermTech news (Ticker: DMTK), a resource for investors and traders seeking the latest updates and insights on DermTech stock.

DermTech, Inc. (symbol: DMTK) is a groundbreaking molecular diagnostic dermatology company dedicated to revolutionizing the diagnosis of skin conditions through innovative non-invasive testing. Located at their CLIA-licensed laboratory in La Jolla, CA, DermTech operates at the cutting edge of dermatological science.

DermTech's core technology focuses on gene expression tests that aid in the clinical diagnosis of skin cancer and other skin conditions. Their flagship product, the Pigmented Lesion Assay (PLA), allows for the analysis of skin biopsy samples using an adhesive patch. This method offers a significant advancement over traditional methods that rely on subjective visual diagnosis and invasive surgical biopsies, which are often prone to error and lead to unnecessary procedures.

The PLA test is designed to detect melanoma in clinically atypical pigmented lesions with high accuracy, providing physicians with critical, objective data to enhance patient care and reduce healthcare costs. By utilizing DermTech’s non-invasive approach, patients experience enhanced comfort and safety during the diagnostic process.

DermTech is committed to advancing the field of dermatology through continuous innovation. In addition to their focus on skin cancer, the company is developing genomic tests to diagnose inflammatory skin diseases and conditions related to aging. These efforts are aimed at providing comprehensive solutions that improve the accuracy of diagnoses and overall patient outcomes.

With a strong emphasis on scientific development and patient care, DermTech partners with various healthcare providers and institutions to expand the availability of their tests. The company generates revenue through their laboratory services, ensuring a sustainable business model while aiming for growth and expanded impact in the dermatology field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.56%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.52%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.07%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
none
-
Rhea-AI Summary
DermTech's Melanoma Test surpasses 200,000 cumulative billable samples, with a negative predictive value of over 99 percent. The test uses non-invasive Smart Stickers™ to detect genomic markers associated with melanoma. The company aims to further integrate the test into the melanoma care pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.07%
Tags
management

FAQ

What is the current stock price of DermTech (DMTK)?

The current stock price of DermTech (DMTK) is $0.094 as of June 27, 2024.

What is the market cap of DermTech (DMTK)?

The market cap of DermTech (DMTK) is approximately 3.3M.

What does DermTech, Inc. specialize in?

DermTech specializes in non-invasive molecular diagnostic tests for skin conditions, focusing on skin cancer and other dermatological issues.

How does DermTech's Pigmented Lesion Assay (PLA) work?

The PLA uses an adhesive patch to collect skin biopsy samples non-invasively, providing accurate gene expression analysis for melanoma detection.

Where is DermTech, Inc. located?

DermTech, Inc. is headquartered in La Jolla, CA, where they operate a CLIA-licensed laboratory.

What makes DermTech's diagnostic method unique?

DermTech's method is non-invasive, removing the need for surgical biopsies and providing objective, accurate data for better diagnosis.

What other skin conditions does DermTech focus on?

In addition to skin cancer, DermTech is developing tests for inflammatory skin diseases and aging-related conditions.

How does DermTech improve patient care?

DermTech improves patient care by offering non-invasive, highly accurate diagnostic tests, reducing unnecessary procedures and enhancing comfort.

Is DermTech's technology widely available?

DermTech partners with various healthcare providers and institutions to expand the availability of their innovative diagnostic tests.

How does DermTech generate revenue?

DermTech generates revenue through its laboratory services, offering non-invasive genomic tests to healthcare providers and institutions.

What is DermTech's mission?

DermTech aims to revolutionize dermatological diagnostics through innovative, non-invasive testing methods, improving accuracy and patient outcomes.

What recent achievements has DermTech made?

DermTech continues to innovate in molecular diagnostics, expanding their test offerings and establishing partnerships to enhance their market presence.

DermTech, Inc.

Nasdaq:DMTK

DMTK Rankings

DMTK Stock Data

3.29M
34.96M
2.62%
18.09%
8.64%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
SAN DIEGO